Core Laboratories Inc

Core Laboratories NV engages in the provision of proprietary and patented reservoir description, production enhancement, and reservoir management services to the oil and gas industry. It operates through the following business segments: Reservoir Description and Production Enhancement. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid, and gas samples and provides analytical and field services to characterize properties of crude oil and petroleum products. The Production Enhancement segment provides products and services relating to reservoir well completions, perforations, stimulations, and production. The company was founded in 1936 and is headquartered in Amsterdam, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Core Labs reports strong Q4 performance, eyes growth opportunities

Core Laboratories Inc delivered a solid performance in Q4 2022, focusing on financial strength, operational efficiency, and future growth prospects. Despite facing challenges from external factors, the company remains optimistic about opportunities in the energy sector and its ability to create value for shareholders.

Core Laboratories Inc reports robust Q1 earnings, eyes EOR opportunities

Core Laboratories Inc delivered strong financial results, highlighted operational efficiencies, and outlined growth strategies amidst industry challenges. The company's focus on innovation, debt reduction, and cost savings bodes well for future performance and shareholder value.

Core Labs reports solid Q2 performance, eyes international growth

Core Laboratories Inc showcased strong financial performance in Q2 2023, with a focus on operational efficiency and technological advancement.
The company's commitment to maximizing free cash flow, returns on invested capital, and shareholder value underscores its financial discipline and strategic priorities.
Despite challenges in the US land sector, Core Labs remains optimistic about international growth opportunities and technological advancements driving future success.

Core Laboratories Inc reports strong Q3 performance amidst market challenges

Core Laboratories Inc delivered a strong Q3 performance with improvements in key financial metrics. While facing challenges in certain segments, the company's strategic focus on innovation and efficiency positions it well for future opportunities. Core Labs remains optimistic about its outlook and is committed to driving growth and value for shareholders.

Core Laboratories reports steady Q4 performance amidst operational challenges

Core Laboratories navigated challenges in Q4 with a focus on debt reduction, innovation, and operational excellence, showcasing resilience and adaptability.
While facing headwinds in certain segments, Core Labs remains committed to long-term sustainability, shareholder value, and technological advancement.
Strategic initiatives and operational highlights underscore Core's leadership in the industry, setting the stage for future growth and market expansion.

Core Labs maintains steady performance amidst geopolitical challenges and debt reduction

Core Laboratories Inc delivered a resilient performance in Q1 2024, focusing on operational efficiency and debt reduction amidst external challenges.
The company's strategic strengths lie in international growth prospects, technology investments, and commitment to financial stability.
Challenges from geopolitical conflicts and operational disruptions highlight the need for adaptability and diversification in Core Labs' business approach.
Opportunities abound in capitalizing on international growth, technology advancements, and maximizing return on invested capital for sustainable growth.

Core Laboratories reports revenue growth and debt reduction in Q3

Core Laboratories Inc delivered a solid financial performance in Q3 2024, with revenue growth, improved margins, and reduced debt levels.
While facing challenges in a competitive market and capital expenditure constraints, the company remains focused on sustaining profitability and operational efficiency.
Opportunities lie in leveraging segment revenue growth, debt reduction strategies, and exploring new avenues for expansion and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Core Laboratories Inc. provides proprietary and patented reservoir description and production enhancement services. The company was founded on May 1, 2023 and is headquartered in Houston, TX.

Dublin, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The "Clinical Chemistry and Immunoassay Industry, Global, 2023-2028" report has been added to ResearchAndMarkets.com's offering. This analysis examines the global clinical chemistry and immunoassay sector, accounting for the highest share in the in vitro diagnostics (IVD) market. This type of lab-based testing analyzes body fluids (usually blood, urine, or saliva) using integrated/standalone analyzers and a wide range of assays/panels, among other solutions and services to support the diagnosis and treatment of human health. While clinical chemistry instruments and tests target different chemicals in body fluids to evaluate health and the clinical management of patients, immunoassay instruments and tests measure the presence or concentration of analytes in biological liquid by using the binding of antibodies to antigens to identify and measure certain substances. This competitive analysis examines IVD companies that provide a broad menu of clinical chemistry and immunoassay systems, including instruments and consumables.

Clinical Chemistry and Immunoassay Industry Forecast Report to 2028: Integrated and Scalable Core Lab Solutions Driving Transformational Growth

CLB shows strong earnings growth, solid cash flow and innovative technologies, but faces risks from geopolitical tensions, weak U.S. onshore activity and oil price volatility.

Is Now the Right Time to Buy Core Laboratories After Its 12% YTD Rise?

Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?

Why Is Core Laboratories (CLB) Up 11.5% Since Last Earnings Report?

Investors need to pay close attention to CORE LABS INC (CLB) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in CORE LABS INC (CLB) Stock?

Core Laboratories Inc. (NYSE:CLB ) Q3 2024 Earnings Conference Call October 24, 2024 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Chris Hill - Chief Financial Officer Gwen Gresham - Senior Vice President and Head, Investor Relations Conference Call Participants Sean Mitchell - Daniel Energy Partners Stephen Gengaro - Stifel Operator Good day and welcome to the Core Lab Q3 2024 Earnings Conference Call. All participants will be in a listen-only mode.

Core Laboratories Inc. (CLB) Q3 2024 Earnings Call Transcript

CLB expects Reservoir Description revenues of $87.5-$90.5 million and Production Enhancement revenues of $41-$45 million for the fourth quarter of 2024.

Core Laboratories' Q3 Earnings and Sales Beat Estimates

Core Laboratories (CLB) came out with quarterly earnings of $0.25 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.22 per share a year ago.

Core Laboratories (CLB) Q3 Earnings Match Estimates

THIRD QUARTER REVENUE OF $134.4 MILLION, UP 3% SEQUENTIALLY AND OVER 7% YEAR-OVER-YEAR THIRD QUARTER OPERATING INCOME OF $19.8 MILLION; EX-ITEMS, $18.2 MILLION, UP 11% SEQUENTIALLY AND 14% YEAR-OVER-YEAR THIRD QUARTER OPERATING MARGINS, EX-ITEMS, OF 14% UP 100 BPS SEQUENTIALLY THIRD QUARTER GAAP EPS OF $0.25; EX-ITEMS, $0.25, UP 14% SEQUENTIALLY AND YEAR-OVER-YEAR THIRD QUARTER FREE CASH FLOW OF $10.4 MILLION NET DEBT REDUCED BY $11.8 MILLION; DEBT LEVERAGE RATIO REDUCED TO 1.47 COMPANY ANNOUNCES Q4 2024 QUARTERLY DIVIDEND HOUSTON , Oct. 23, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported third quarter 2024 revenue of $134,400,000. Core's operating income was $19,800,000, with diluted earnings per share ("EPS") of $0.25, all in accordance with U.S. generally accepted accounting principles ("GAAP").

CORE LAB REPORTS THIRD QUARTER 2024 RESULTS

Oceaneering

ProPetro Hld

Energy stocks such as PUMP, CLB and OII are poised to deliver a Q3 earnings beat.

Energy Stocks to Watch Amid Q3 Earnings Despite Pricing Pressures

CLB is expected to report higher revenues compared with the previous quarter, along with reduced costs for services and product sales and general administrative expenses.

What's in Store for Core Laboratories Stock in Q3 Earnings?

Core Laboratories (CLB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Core Laboratories (CLB) Keep the Earnings Surprise Streak Alive?

Core Laboratories (CLB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Core Laboratories (CLB) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Core Laboratories (CLB) is a Strong Value Stock

Archrock

Equinor

PEDEVCO

EQNR secures a 9.8% stake in Orsted, becoming the latter's second-largest shareholder and advancing its commitment to offshore wind and renewable energy growth.

Equinor Strengthens Offshore Wind Portfolio With 9.8% Stake in Orsted

Nine Energy Service

Sasol

Buy energy stocks like Sasol (SSL), Core Lab (CLB) and Nine Energy (NINE) for steady returns in a volatile macroeconomic environment.

3 Energy Stocks to Buy on Continued Geopolitical Turmoil

CLB is a compelling investment in the oilfield services sector, featuring strong fundamentals, innovative technologies and a disciplined financial strategy poised for growth.

Is Now the Right Time to Buy Core Laboratories After Its 14% YTD Rise?

Eni SpA Sponsored ADR

E's upstream merger with Ithaca Energy creates a major player in the North Sea, setting the stage for substantial oil and gas production and UK energy security.

Eni-Ithaca Merger Expands Footprint in North Sea Oil and Gas

TechnipFMC

Considering OPEC's optimistic oil demand growth forecast, we recommend buying stocks like CLB, FTI and TUWOY.

OPEC's Forecast of Peak Oil Demand: A Long Horizon Ahead

HOUSTON, Sept. 24, 2024 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will broadcast its third quarter 2024 conference call over the Internet at 7:30 a.m. CDT / 8:30 a.m. EDT on October 24, 2024.

CORE LABORATORIES' THIRD QUARTER 2024 WEBCAST AT 7:30 A.M. CDT / 8:30 A.M.

Here is how Core Laboratories (CLB) and Talen Energy Corporation (TLN) have performed compared to their sector so far this year.

Are Oils-Energy Stocks Lagging CORE LABS INC (CLB) This Year?

The heavy selling pressure might have exhausted for Core Laboratories (CLB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Core Laboratories (CLB) Loses -10.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Here is how Core Laboratories (CLB) and Ranger Energy (RNGR) have performed compared to their sector so far this year.

Is CORE LABS INC (CLB) Stock Outpacing Its Oils-Energy Peers This Year?

Baker Hughes Co

Investors interested in stocks from the Oil and Gas - Field Services sector have probably already heard of Baker Hughes (BKR) and Core Laboratories (CLB). But which of these two companies is the best option for those looking for undervalued stocks?

BKR or CLB: Which Is the Better Value Stock Right Now?

Core Laboratories (CLB) expects Reservoir Description revenues of $86.5-$89.5 million and Production Enhancement revenues of $44.5-$47.5 million for the third quarter of 2024.

Core Laboratories (CLB) Q2 Earnings Beat & Revenues Lag

Core Laboratories Inc. (NYSE:CLB ) Q2 2024 Earnings Call July 25, 2024 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Chris Hill - Chief Financial Officer Gwen Gresham - Senior Vice President and Head, Investor Relations Conference Call Participants John Daniel - Daniel Energy Partners Stephen Gengaro - Stifel Operator Good day and welcome to the Core Laboratories Second Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note that today's event is being recorded.

News for Core Laboratories Inc Stock (CLB)